170729-80-3 | 5-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-2,3-dihydro-1H-1,2,4-triazol-3-one

990-91-0    170729-80-3    265121-01-5 

[1]JournalofMedicinalChemistry,2000,vol.43,p.1234-1241

[2]Patent:CN108948080,2018,A.Locationinpatent:Paragraph0025;0026

[3]Patent:US2007/265442,2007,A1.Locationinpatent:Page/Pagecolumn5-6

[4]Patent:US2011/130366,2011,A1.Locationinpatent:Page/Pagecolumn9

[5]Patent:WO2012/164576,2012,A2.Locationinpatent:Page/Pagecolumn5

[6]Patent:WO2018/211410,2018,A1.Locationinpatent:Page/Pagecolumn13-15

990-91-0    170729-80-3    265121-01-5   

C44H41F7N4O9P2 

[1]JournalofMedicinalChemistry,2000,vol.43,p.1234-1241

252742-72-6   

2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)-phenyl)ethoxy)-3-(S)-(4-fluorophenyl)morpholinep-toluenesulfonate 

  170729-80-3 

[1]TetrahedronLetters,2000,vol.41,p.8661-8664

252742-72-6    171338-27-5    170729-80-3 

[1]Patent:WO2009/106486,2009,A1.Locationinpatent:Page/Pagecolumn18

[2]JournalofOrganicChemistry,2002,vol.67,p.6743-6747

252742-72-6   

2R-2α(R*),3α-2-1-3,5-bis(trifluoromethyl)phenylethoxy-3-(4-fluorophenyl)morpholinehydrochloride 

  170729-80-3 

[1]JournaloftheAmericanChemicalSociety,2003,vol.125,p.2129-2135

Title: Utilization of human nuclear receptors as an early counter screen for off-target activity: a case study with a compendium of 615 known drugs.

Journal: Toxicological sciences : an official journal of the Society of Toxicology 20150601

Title: Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.

Journal: Chemical research in toxicology 20150518

Title: Use of high-dose cisplatin with aprepitant in an outpatient setting.

Journal: European journal of cancer care 20120701

Title: [The efficacy of aprepitant and palonosetron on cisplatin doublet in lung cancer].

Journal: Gan to kagaku ryoho. Cancer & chemotherapy 20111001

Title: Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC).

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20110901

Title: Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20110801

Title: Pemirolast reduces cisplatin-induced kaolin intake in rats.

Journal: European journal of pharmacology 20110701

Title: [Retrospective analysis of antiemetic effect in patients receiving cisplatin].

Journal: Gan to kagaku ryoho. Cancer & chemotherapy 20110701

Title: The involvement of TRPA1 channel activation in the inflammatory response evoked by topical application of cinnamaldehyde to mice.

Journal: Life sciences 20110620

Title: Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110410

Title: Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clinical candidate.

Journal: Journal of medicinal chemistry 20110224

Title: Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin.

Journal: Cancer science 20101101

Title: Case report: delirium due to a diltiazem-fentanyl CYP3A4 drug interaction.

Journal: General hospital psychiatry 20100101

Title: The tachykinin NK3 receptor agonist senktide induces locomotor activity in male Mongolian gerbils.

Journal: European journal of pharmacology 20081214

Title: Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 20080901

Title: Metalloelastase in lungs and alveolar macrophages is modulated by extracellular substance P in mice.

Journal: American journal of physiology. Lung cellular and molecular physiology 20080701

Title: Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology 20070401

Title: Central neurocircuitry associated with emesis.

Journal: The American journal of medicine 20011203

Title: Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs.

Journal: Journal of medicinal chemistry 20000323

Title: Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist.

Journal: Journal of medicinal chemistry 19981105

Title: Martinez AN, et al. Aprepitant limits in vivo neuroinflammatory responses in a rhesus model of Lyme neuroborreliosis. J Neuroinflammation. 2017 Feb 15;14(1):37.

Title: Bayati S, et al. Inhibition of tachykinin NK1 receptor using aprepitant induces apoptotic cell death and G1 arrest through Akt/p53 axis in pre-B acute lymphoblastic leukemia cells. Eur J Pharmacol. 2016 Nov 15;791:274-283.

Title: Mannangatti P, et al. Differential effects of aprepitant, a clinically used neurokinin-1 receptor antagonist on the expression of conditioned psychostimulant versus opioid reward. Psychopharmacology (Berl). 2017 Feb;234(4):695-705.

Title: Barrett JS, et al. Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV. J Transl Med. 2016 May 26;14(1):148.